New hope in prediabetes treatment: Homeopathy exceeds placebo
New hope in prediabetes treatment: Homeopathy exceeds placebo
The latest research, published in May 2024, dealt with the effectiveness of individualized homeopathic drugs (it) compared to placebos in the treatment of prediabetes (PD), a state that is a significant disease burden worldwide and increases the risk of stroke, cardiovascular diseases and type 2 diabetes mellitus. In this study, which was carried out over a period of six months at the outpatient departments of a homeopathic medical document and hospital in India, 60 participants with PD were either randomized to a group with the (30 people) or to a placebo group (30 people). In addition, both groups received advice on nutrition, yoga, meditation and exercises.
The main rating criteria of the study were sober blood sugar (FBS) and the oral glucose tolerance test (OGTT), while the secondary criterion of diabetes symptom Checklist-Revised (DSC-R) score was used. All results were measured at the beginning, after three and after six months of treatment. The researchers found that the significantly better results in FBS and DSC-R-Score, which were significantly better compared to placebos, did not show the OGTT. It is noteworthy that no damage or serious undesirable events were observed among the participants.
The results suggest that he could represent an effective treatment option for people with PD, especially with regard to the improvement of FBS values and the quality of life, measured by the DSC-R-Score. These findings could lead to a review and possible adaptation of existing treatment practices, although independent repeat studies with larger samples are required to confirm the results.
The most important terms and concepts briefly explained:
- Prediabetes (PD): A state of health in which the blood sugar level is higher than normal, but not high enough to be diagnosed as type 2 diabetes. Increases the risk of type 2 diabetes, cardiovascular diseases and strokes.
- Homeopathic medication (him): treatments that "similar to the same may be healed by the like", in which very diluted substances are used, which are assumed that if they are taken in higher doses, they could cause symptoms similar to the disease to be treated.
- sober blood sugar (FBS): A blood sample that is taken after a nightly fasting period to determine the blood sugar level.
- oral glucose tolerance test (OGTT): A test that measures how well the body processes glucose. The participant is given a sugar -based solution and then measured the blood sugar level at several times.
- Diabetes Symptom Checklist-Revised (DSC-R): an instrument for self-assessment that is used to assess the symptoms and quality of life of people with diabetes or prediabetes.
This simplified explanation is intended to help better understand the importance of these research results in the context of prediabetes treatment and to recognize its potential role in future medical practice.
Significant improvement of sober -blood sugar levels through individualized homeopathic drugs compared to placebos in prediabetes
The present study examined the effectiveness of individualized homeopathic medication (it) compared to placebos in the treatment of prediabetes, a preliminary stage to more serious diseases such as stroke, cardiovascular diseases and type 2 diabetes mellitus. Research aims to gain new knowledge about alternative treatment options for prediabetes and was carried out in the outpatient departments of a homeopathic medical colleges and hospital in India over a period of six months by means of a double -blind, randomized, placebo -controlled study.
methodology
The study included 60 participants with prediabetes who received either (n = 30) or identical looking placebos (n = 30). Accompanying measures such as nutritional advice, yoga, meditation and exercises were recommended to both groups of participants. Sober blood sugar (FBS) and the oral glucose tolerance test (OGTT) were determined as the primary result dimensions, while the diabetes symptom of Checklist-Revised (DSC-R) score served as a secondary result. The evaluations took place at the beginning of the study and after 3 and 6 months of treatment. For the statistical analysis, intergruppal differences and effect sizes (Cohen’s D) were calculated using two-way variance analyzes with repeated measurements, whereby Baseline differences using covariating analysis were adjusted taking into account the intention-to-ex-step data.
results
The differences between the groups in the FBS values were statistically significant and spoke for which he spoke compared to the placebos (f = 7.798, p = 0.007). In the OGTT values, however, no significant difference was determined (f = 1,691, p = 0.199). The overall DSC-R showed a significant improvement in favor of the placebos (f = 15,752, p <0.001). Lycopodium, phosphorus and nux vomica were the most frequently prescribed medication. No damage or serious undesirable events were recorded in both groups of participants.
conclusion
The study demonstrates that he achieved significantly better results than placebos in improving the FBS values and the DSC-R scores, but not with the OGTT values. These results provide a promising outlook on the use of him in the treatment of prediabetes, but independent replications with larger samples are required to underpin the findings.